Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Vyleesi™, the trade name for Br...
Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Vyleesi™, the trade name for Bremelanotide, for the treatment of hypoactive sexual desire disorder (HSDD) is our lead product. A New Drug Application for approval of Vyleesi was approved by the Food and Drug Administration (FDA) in June 2019.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.